Form 10-Q · Quarterly report
Eli Lilly 10-Q, filed Aug 5, 2026
- Filed
- CIK
- 0000059478
- Accession no.
- 0000059478-26-000081
Summary
Eli Lilly reported second-quarter 2026 revenue of $22.97 billion, up 48% from a year earlier, and net income of $7.10 billion ($7.94 per diluted share), growth it attributed to higher volume partially offset by lower realized prices, primarily for Mounjaro and Zepbound. Lilly said the FDA approved orforglipron (Foundayo) for obesity, that Phase 3 trials of retatrutide for obesity and type 2 diabetes met their primary endpoints, and that it submitted orforglipron for type 2 diabetes in the U.S., EU, and Japan.
Key points
- Six-month 2026 revenue was $42.77 billion versus $28.29 billion a year earlier, with net income of $14.49 billion and diluted EPS of $16.19.
- Mounjaro and Zepbound accounted for 65% of total revenue for the six months ended June 30, 2026.
- Medicare beneficiaries gained access to discounted Lilly obesity medicines under the Medicare GLP-1 Bridge program effective July 1, 2026 through December 31, 2027.
- Under the Inflation Reduction Act, HHS selected Jardiance (effective 2026) and Trulicity and Verzenio (effective 2028) for government-set Medicare prices.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion EXECUTIVE OVERVIEW This section provides an overview of our financial results, updates to our clinical development pipeline, and other matters affecting our company and industry. Financial Results The following table summarizes certain financial information: Three Months Ended June 30, Percent Change Six Months Ended June 30, Percent Change 2026 2025 2026 2025 Revenue $ 22,974 $ 15,558 48 $ 42,773 $ 28,286 51 Net income 7,095 5,661 25 14,491 8,420 72 Earnings per share - diluted 7.94 6.29 26 16.19 9.35 73 Revenue increased for the three and six months ended June 30, 2026, driven primarily by increased volume, partially offset by lower realized prices. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.